brivanib

Ligand id: 5671

Name: brivanib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 84.67
Molecular weight 370.14
XLogP 2.37
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Brivanib is in Phase III clinical trials for liver and colorectal cancers. Click here to link to ClinicalTrials.gov's listing of Phase III brivanib trials. Phase II studies for endometrial cancer, renal cell cancer (RCC) and other solid tumours are ongoing (view the full list here).
Mechanism Of Action and Pharmacodynamic Effects
Like other angiokinase inhibitors, brivanib's anti-neoplastic effect is due to its suppression of the neo-angiogenesis required for tumour growth and expansion [1].